Breaking News
April 26, 2019 - Porvair Sciences’ ultra-flat Krystal glass bottom microplates for imaging applications
April 26, 2019 - Medicines Discovery Catapult’s Virtual R&D Discovery Services platform announce twenty-two partnerships
April 26, 2019 - How optimism can bias prognosis in serious illness
April 26, 2019 - Hospitals Chafe Under Medicare’s New Payment Rule For Off-Campus Clinics
April 26, 2019 - New drug minimizes damage after a heart attack by 60 percent
April 26, 2019 - Synthesizing Modified and Pharmaceutically Relevant Peptides
April 26, 2019 - Using blood thinners in heart failure patients associated with reduced risk of thromboembolic events
April 26, 2019 - Study finds different amounts of physical therapy for stroke patients
April 26, 2019 - Psychologists study how application of cortisol affects exposure therapy for anxiety disorders
April 26, 2019 - SibFU scientists create multilayer gilded nanodisks for medical applications
April 26, 2019 - Marking the start of Pediatric Sepsis Week
April 26, 2019 - The Inflamed Brain | NIH News in Health
April 26, 2019 - Stress-free training may enhance surgical skill
April 26, 2019 - Newsom: California Leads On Prescription Drugs
April 26, 2019 - Exploring novel strategies to heal damage after a heart attack
April 26, 2019 - Small army of tiny robots can remove dental plaque
April 26, 2019 - Cellular communication in emotion-processing brain region motivates us to keep eating tasty food
April 26, 2019 - Greater spousal life satisfaction associated with lower mortality risk
April 26, 2019 - Genetic mutations in brain development lead to discovery of rare genetic diseases
April 26, 2019 - Speech-Based Algorithm Helps ID Posttraumatic Stress Disorder
April 26, 2019 - First birth via robot-assisted uterus transplant
April 26, 2019 - Studies verify novel method of HIV transmission among injection drug users and effective prevention
April 26, 2019 - CircRNAs bind to dsRNA-activated protein kinase which is linked to innate immunity
April 26, 2019 - MR Solutions wins third Queen’s Award
April 26, 2019 - Study details how optimism can bias prognosis in serious illness
April 26, 2019 - Vascular surgery after firearm injury linked with higher morbidity and mortality
April 26, 2019 - New findings about aggressive blood cancer may help develop drugs with less harmful side effects
April 26, 2019 - People with intense feelings of responsibility susceptible to developing OCD, anxiety
April 26, 2019 - Despite expansion of insurance coverage for depression, treatment rates are lower than expected
April 26, 2019 - Huge Malaria vaccine trial in Malawi
April 26, 2019 - Can Obesity Shrink Your Brain?
April 26, 2019 - This oral appliance could help you (and your partner) sleep better
April 26, 2019 - Myelination deficits cause abnormal hypersocial behavior associated with Williams syndrome
April 26, 2019 - New sepsis detector uses photonics to make accurate diagnosis in less than thirty minutes
April 26, 2019 - New study describes process to diagnose rare genetic diseases in record time
April 26, 2019 - Scientists and patients gather in Vancouver to discuss about Stevens-Johnson syndrome
April 26, 2019 - Advance in breakthrough cancer treatment eliminates serious side effects
April 26, 2019 - Discovery about cold sensing could pave way for new pain relief drugs
April 26, 2019 - Children often turn to sugary drinks instead of water
April 26, 2019 - Genome analysis shows the combined effect of many genes on cognitive traits
April 26, 2019 - Patients Caught In Middle Of Fight Between Health Care Behemoths
April 26, 2019 - Drug overdoses among adolescents and young adults on the rise
April 26, 2019 - Implementing a Paperless QC Micro Laboratory”
April 25, 2019 - Obesity linked to a reduction in gray matter
April 25, 2019 - Smart assistants could help combat opioid crisis
April 25, 2019 - Diagnostic stewardship strategy reduces inappropriate testing
April 25, 2019 - Three-antibiotic cocktail eradicates ‘persister’ Lyme bacteria in mouse model
April 25, 2019 - Study investigates how early blindness shapes sound processing
April 25, 2019 - Outcomes Worse for Cancer Patients Seen at Noncancer EDs
April 25, 2019 - Link found between temperament of high-risk infants and obesity
April 25, 2019 - Al Letson explores ties between journalists and doctors at Medicine and the Muse symposium
April 25, 2019 - New mobile phone game can detect people at risk of Alzheimer’s
April 25, 2019 - Scientists discover trigger region for absence epileptic seizures
April 25, 2019 - Stretchy wearable patch can do a health check while you work out
April 25, 2019 - Exercise activates brain circuits associated with memory in older adults
April 25, 2019 - Veggies, Fruits and Grains Keep Your Heart Pumping
April 25, 2019 - Healthy meal kits can boost children’s long-term health
April 25, 2019 - Designing an inexpensive surgical headlight: A Q&A with a Stanford surgeon
April 25, 2019 - States Weigh Banning A Widely Used Pesticide Even Though EPA Won’t
April 25, 2019 - Integrator complex proteins are crucial for healthy brain development in fruit flies, study finds
April 25, 2019 - Device converts brain signals into speech, offering hope for patients
April 25, 2019 - Measles vaccination rates are a ‘public health time bomb’
April 25, 2019 - Maths made easier for scientists students who shun the subject wins award
April 25, 2019 - Researchers decode how cancer drug works in brains of Parkinson’s disease patients
April 25, 2019 - Smarter Brain Cancer Trial Comes to Columbia
April 25, 2019 - Researchers Seek Sage Advice Of Elders On Aging Issues
April 25, 2019 - New chemical synthesis strategy leads to identification of novel, simpler derivatives
April 25, 2019 - Vanderbilt investigators discover link between vascular biology and eye disease
April 25, 2019 - Feces transplantation is effective and provides economic benefits
April 25, 2019 - Eisenhower Health first in Southern California to offer new lung valve treatment for COPD/emphysema
April 25, 2019 - Johns Hopkins researchers uncover role of neurotransmitter in the spread of aggressive cancers
April 25, 2019 - Porvair Sciences offers highly effective P3 microplate for biological sample clean-up
April 25, 2019 - Air pollution increases risk for respiratory hospitalization among childhood cancer survivors
April 25, 2019 - We are sitting more! How bad is that?
April 25, 2019 - Majority of stroke survivors not screened for osteoporosis, despite increased risk
April 25, 2019 - ADHD Screening: MedlinePlus Lab Test Information
April 25, 2019 - Cellular alterations increase vulnerability of obese and diabetic individuals to infection
April 25, 2019 - Association Insurance Pushes On Despite Court Ruling
April 25, 2019 - Traditional and e-cigarette users may be more receptive to smoking cessation interventions
April 25, 2019 - Delving into tumor’s cellular lineage may offer clues for customized therapies
Researchers describe promising strategy to remove melanoma’s most powerful defenses

Researchers describe promising strategy to remove melanoma’s most powerful defenses

image_pdfDownload PDFimage_print

Immunotherapies use the immune system to fight cancer. But cancers like melanoma have found ways to turn off the immune system, allowing them to resist treatments and often leading to recurrence. Now University of Colorado Cancer Center clinical trial results published today in the journal International Immunopharmacology describe a promising strategy to remove one of melanoma’s most powerful defenses: By adding retinoic acid to standard-of-care treatment, researchers were able to turn off myeloid-derived suppressor cells (MDSCs) that turn off the immune system, leading to more immune system activity directed at melanoma.

“The immune response and MDSCs are like yin and yang, balancing each other. For example, you want the immune system to fight an infection and then you want MDSCs to shut down the immune system when the infection is gone,” says Martin McCarter, MD, investigator at the CU Cancer Center and surgical oncologist at the UCHealth University of Colorado Hospital.

“We started studying our melanoma patients and found a ton of these MDSCs in the circulation and in the tumor itself,” he says. “Melanoma induces these cells to be around the tumor microenvironment. After identifying that, yes, there are a lot of these cells around, we wanted to find ways to target those MDSCs. If we could render them dysfunctional then in theory a better immune response could go forward.”

Working in the McCarter lab with initial funding from a grateful patient, then-postdoctoral researcher Kim Jordan, PhD, studied ways to alter MDSC function and “identified a promising drug called all-trans retinoic acid or ATRA,” McCarter says.

Understanding how retinoic acid defuses MDSCs requires a little knowledge about each.

MDSCs are immature, undifferentiated cells that are produced in the bone marrow. When healthy, MDSCs quickly mature into cell types that aid immune function. But cancers like melanoma encourage MDSCs to remain immature, and this population of immature MDSCs turns off the immune system.

Retinoic acid is a well-known compound derived from the breakdown of Vitamin A. It encourages cells to differentiate, transitioning from stem-like cells into the mature cells the body needs for structure and function. Retinoic acid is a common ingredient in topical acne treatments and is also used to treat acute promyelocytic cancer. Work in the McCarter lab and elsewhere showed that the form of retinoic acid known as ATRA could force MDSCs to mature, switching their function from immune suppression to immune support.

“ATRA was available off the shelf. There was a lot of history and lot of knowledge about the drug itself,” McCarter says.

Based on promising laboratory work, Dr. Jordan wrote a proposal for an R21 grant, also known as an Exploratory/Development Grant, which is a program by the National Institutes of Health meant to encourage researcher-initiated trials.

“We wanted to take standard-of-care treatment and add ATRA,” McCarter says.

At the time, standard-of-care treatment included the drug ipilimumab, which is a checkpoint inhibitor targeting a protein called CTLA-4, which helps release the brakes on the immune system so that it can target cancer. The study enrolled 10 patients, with half receiving ipilimumab alone and half receiving ipilimumab plus ATRA.

“We were able to show several things,” McCarter says. “First is that we could reduce the number of circulating MDSCs in patients that got ATRA. We also showed that immunosuppressive MDSC genes were reduced in these patients. And we showed there was more activation of CD8 T cells. Basically, not only did immunosuppressive stuff go down, but the immune response went up. The other take-home is this was a safe combination – adding ATRA didn’t increase toxic side-effects.”

Then, partway through the trial, ipilimumab stopped being the standard of care. Instead of using ipilimumab to help the immune system target CTLA-4, doctors started using drugs like pembrolizumab and nivolumab to target PD-1.

“We didn’t have enough patients on the trial to show survival benefit but we were able to demonstrate the proof of principal to target MDSCs in humans,” McCarter says.

Meanwhile, McCarter’s postdoctoral researcher, Kim Jordan, took a position as an associate research professor in the CU School of Medicine Department of Immunology. Luckily, she was replaced by another postdoctoral researcher, Richard Tobin, PhD, who was able to shepherd the group’s promising preclinical work with ATRA and MDSCs from ipilimumab to pembrolizumab. A new trial of pembrolizumab with and without ATRA offered at the UCHealth University of Colorado Hospital to adult patients with stage III or IV melanoma has started enrollment and is recruiting patients (ClinicalTrials.gov #NCT03200847).

“This is a homegrown project, from the basic laboratory work, through the translational science, and now into investigator-initiated clinical trials,” McCarter says. “I couldn’t be more proud of Kim, Richard and the rest of my team. And we see the real potential that this strategy could be a useful and non-toxic addition to immunotherapies for patients with melanoma.”

The group expects results of the current trial of pembrolizumab plus ATRA in late 2019.

Tagged with:

About author

Related Articles